Corrects share movement to 41%, not 412%, in first bullet
** Shares of contract research organization Medpace MEDP.O rise 41% to $440.02 in extended trading
** Co forecasts 2025 sales to be between $2.42 billion and $2.52 billion, up from prior range of $2.14 billion to $2.24 billion
** Analysts were expecting 2025 sales to be $2.19 billion — LSEG data
** Co posts Q2 sales of $603.3 million, above est of $538.8 million
** Co reports Q2 net income of $90.3 million, compared to $88.4 million a year ago
** Co also forecasts 2025 non-adjusted earnings per share in the range of $13.76 to $14.53
** Stock down 7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.